Brokerages Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $41.75

by · The Cerbat Gem

Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $41.75.

Several research firms recently issued reports on VRDN. Wall Street Zen upgraded shares of Viridian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Truist Financial set a $41.00 target price on Viridian Therapeutics in a report on Monday, November 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Wednesday, October 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $40.00 price target on shares of Viridian Therapeutics in a research report on Thursday, November 6th. Finally, BTIG Research reiterated a “buy” rating and set a $61.00 price objective on shares of Viridian Therapeutics in a research note on Tuesday, November 4th.

View Our Latest Report on VRDN

Insider Activity

In other news, Director Fairmount Funds Management Llc bought 454,545 shares of the company’s stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average price of $22.00 per share, for a total transaction of $9,999,990.00. Following the transaction, the director directly owned 3,914,458 shares of the company’s stock, valued at $86,118,076. This trade represents a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.58% of the stock is owned by company insiders.

Institutional Trading of Viridian Therapeutics

Several hedge funds have recently modified their holdings of VRDN. Aster Capital Management DIFC Ltd acquired a new position in shares of Viridian Therapeutics in the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC boosted its stake in Viridian Therapeutics by 332.1% in the third quarter. Farther Finance Advisors LLC now owns 1,940 shares of the company’s stock worth $42,000 after purchasing an additional 1,491 shares in the last quarter. Bessemer Group Inc. boosted its stake in Viridian Therapeutics by 947.7% in the third quarter. Bessemer Group Inc. now owns 2,085 shares of the company’s stock worth $45,000 after purchasing an additional 1,886 shares in the last quarter. Larson Financial Group LLC bought a new stake in shares of Viridian Therapeutics during the third quarter worth $52,000. Finally, US Bancorp DE increased its stake in shares of Viridian Therapeutics by 23.2% in the third quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after buying an additional 463 shares in the last quarter.

Viridian Therapeutics Stock Up 0.3%

VRDN opened at $31.12 on Monday. The company has a market capitalization of $2.97 billion, a P/E ratio of -10.30 and a beta of 0.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 11.28 and a quick ratio of 11.28. The firm’s fifty day moving average price is $29.38 and its two-hundred day moving average price is $22.18. Viridian Therapeutics has a fifty-two week low of $9.90 and a fifty-two week high of $34.04.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.48. Viridian Therapeutics had a negative net margin of 426.58% and a negative return on equity of 78.50%. The company had revenue of $70.57 million during the quarter, compared to analysts’ expectations of $16.21 million. The business’s quarterly revenue was up 81993.0% on a year-over-year basis. On average, analysts anticipate that Viridian Therapeutics will post -4.03 EPS for the current year.

Viridian Therapeutics Company Profile

(Get Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

Recommended Stories